S.L

Company snapshot

S.L is a pharma organization headquartered in SAN DIEGO, CA, EU. It trades on NYSE under ticker CNTB. Primary therapeutic focus areas include Patency of the Ductus Arteriosus, Atopic Dermatitis, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis, Moderate to Severe Persistent Asthma. NovaPharmaNews links 15 clinical program(s), 0 drug profile(s), and 179 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (7), phase 1 (6), phase 3 (2).

• 15 active pipeline program(s) linked via ClinicalTrials.gov.
• 179 US patent(s) indexed to this assignee profile.
• 15 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for S.L. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for S.L.

1. Jun 8, 2026 Clinical update

   CBP-201-CN004 — Phase 1

2. Jun 8, 2026 Clinical update

   vitamin D3 — Phase 1

3. Jun 8, 2026 Clinical update

   umbilical cord blood (hUCB) cells — Phase 2

4. Jun 8, 2026 Clinical update

   Glycerol Phenylbutyrate 1100 MG/ML [Ravicti] — Phase 1

5. May 23, 2026 Clinical update

   Acetaminophen — Phase 3

View all clinical trial activity →

• What is S.L?

  S.L is a pharma organization headquartered in SAN DIEGO, CA, EU. It trades on NYSE under ticker CNTB. Primary therapeutic focus areas include Patency of the Ductus Arteriosus, Atopic Dermatitis, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis, Moder

• Is S.L publicly traded?

  Yes. S.L is listed with ticker CNTB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does S.L develop or market?

  We link 11 drug profile(s) where S.L is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/connect-biopharma-holdings-ltd#company-drugs.

• What are the latest developments for S.L?

  In the last 12 months our linked public records show 15 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does S.L focus on?

  S.L focuses on Patency of the Ductus Arteriosus, Atopic Dermatitis, Chronic Rhinosinusitis With Nasal Polyps based on our analysis of their pipeline programs and drug development activities.